All Oncology News

Daniel P. Petrylak, MD, discusses the importance of molecularly-driven clinical trials and ongoing research with novel therapeutics in urothelial carcinoma.

Anthony Villano, MD, and Joceline Vu, MD, were recently elected members of the Education Committee of the Association for Academic Surgery.

The cancer vaccine immunotherapeutic VBI-1901 generated disease control in patients with recurrent glioblastoma.

The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.

Keeping investigators on the edge of their seats, new data from clinical trials evaluating ADCs continue to impress.

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.

Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute.

Treatment with GRANITE showed early signals of activity following frontline induction chemotherapy in metastatic microsatellite stable colorectal cancer.

A rolling BLA for zanidatamab in previously treated, HER2-positive, advanced biliary tract cancer has been submitted to the FDA.

The new drug application for sintilimab plus fruquintinib has been granted priority review by the NMPA for pMMR/non-MSI-H advanced endometrial cancer.

The EMA has accepted a MAA seeking the approval of obe-celf or use in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia.

The FDA has accepted a biologics license application for datopotamab deruxtecan in HR-positive, HER2-negative metastatic breast cancer.

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

Lindsay Wilde, MD, explains when cannabis may be appropriate and how she’s seen the agent affect quality of life for her patients.

Bernard H. Bochner, MD, FACS, highlights advancements in early-stage muscle-invasive bladder cancer and the necessity for multimodality approaches.

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.

Richard T. Lee, MD, discusses integrative oncology approaches and the development of the Cherng Family Center for Integrative Oncology at City of Hope.

The FDA has approved danicopan as add-on therapy to ravulizumab or eculizumab for extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

Sylvester Comprehensive Cancer Center and NANETS will present a regional educational conference focusing on neuroendocrine tumors.

Utidelone injectable has received FDA orphan drug designation for patients with breast cancer brain metastases.

The incorporation of immune checkpoint inhibitors has altered the treatment paradigm for endometrial cancer.

A survey of practicing oncologists in the United States revealed that clinicians have ethical concerns surrounding the use of AI in cancer care.

Daniel P. Petrylak, MD, discusses advancements in the treatment of patients with bladder cancer.

Health systems have put a stronger emphasis on making preventive care accessible, contributing to a reduction in colorectal cancer incidence and mortality.

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.

Shivaani Kummar, MBBS, FACP, discusses the mechanism of action of the TP53-directed agent rezatapopt and efficacy data with this agent in solid tumors.

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.